/
Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals.
$33.31
$1.21 (-3.51%)
EOD Jul 17, 2026
Operating margin is thin at 8.52%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue up 27.4% YoY with margins expanding 6.2pp. However, free cash flow softened 10%, worth monitoring whether this is timing or structural.
Even for strong businesses, today's 14x P/E means the stock needs to keep delivering. There's no margin of safety if growth disappoints.
14.2x earnings, 107.0x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$1.50B
▲ +27.4% YoY
Net Income (TTM)
$95M
▲ +1897.7% YoY
Op. Margin
12.00%
▲ +6.2pp YoY
ROIC
17.51%
▲ +16.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$13M
▼ -9.8% YoY
Op. Cash Flow (TTM)
$66M
▼ -8.5% YoY
Net Debt
$595M
Cash & Equiv.
$77M
5Y CAGR: +10.1%
5Y CAGR: +10.6%
Continue Research
At a P/E of 14.2 and a price-to-free-cash-flow of 107.0, Phibro Animal Health (PAHC) trades above a two-stage DCF intrinsic value of about $-9.11 per share, so at $33.31 the stock looks overvalued (127.3% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Phibro Animal Health scores 59/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 1.4%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $-9.11 per share for PAHC, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $-6.83. At today's $33.31, that puts the stock about 127.3% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Phibro Animal Health scores 59 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a 12.0% operating margin and a 17.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Phibro Animal Health pays a regular dividend of about $0.47 per share per year (typically in quarterly installments), a yield of roughly 1.4% at the current price. That is a payout ratio of about 20.4% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For PAHC's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. PAHC currently trades above its estimated intrinsic value and scores 59/100 on quality (mixed). It also yields about 1.4%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.